• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Celgene Corporation (CELG) - Financial and Strategic SWOT Analysis Review - Product Image

Celgene Corporation (CELG) - Financial and Strategic SWOT Analysis Review

  • Published: March 2013
  • Region: Global
  • 55 pages
  • GlobalData

FEATURED COMPANIES

  • Amgen Inc.
  • Eisai Co., Ltd.
  • Genta Incorporated
  • Merck & Co., Inc.
  • Shire Plc
  • MORE

Summary

Celgene Corporation (Celgene) is a biopharmaceutical company. It carries out the research, development, manufacture, and marketing of therapies designed to treat cancer and immune-inflammatory-related diseases. The company's product portfolio includes Revlimid (lenalidomide), Vidaza, Thalomid (thalidomide), Abraxane and Istodax. The company also has several products at various stages of development for the treatment of hematological and solid tumor cancers, which include multiple myeloma, myelodysplastic syndromes, non-Hodgkin's lymphoma (NHL), myelofibrosis, chronic lymphocytic leukemia (CLL), small cell lung cancer and prostate cancer.

Celgene Corporation Key Recent Developments

Mar 21, 2013: Celgene And bluebird bio To Collaborate With Center For Cell And Gene Therapy To Advance New And Existing CAR T-cell Programs
Mar 04, 2013: Industry Leaders And Academic Researchers Come Together For Innovative Accelerating Cancer Cures Research Symposium
Jan 24, 2013: Celgene Reports Revenue Of $1.45 Billion In Q4 2012
Oct 25, 2012: Celgene Reports Revenue Of $1.4 Billion In Q3 2012
Oct 03, 2012: Leukemia & Lymphoma Society And Celgene Enter Into READ MORE >

List of Tables
List of Figures
Section 1 - About the Company
Celgene Corporation - Key Facts
Celgene Corporation - Key Employees
Celgene Corporation - Key Employee Biographies
Celgene Corporation - Major Products and Services
Celgene Corporation - Pharmaceutical Pipeline Products Data
Celgene Corporation, Pipeline Products by Therapy Area
Celgene Corporation, Pipeline Products by Development Phase
Celgene Corporation - History
Celgene Corporation - Company Statement
Celgene Corporation - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Celgene Corporation - Business Description
Celgene Corporation - Corporate Strategy
Celgene Corporation - SWOT Analysis
SWOT Analysis - Overview
Celgene Corporation - Strengths
Strength - Focus on Research and Development
Strength - Intellectual Property Portfolio
Strength - Alliances & Partnerships
Strength - Sound Profitability Indicators
Celgene Corporation - Weaknesses
Weakness - Litigations and Legal Issues
Weakness - CGMP Negative Opinion
Celgene Corporation - Opportunities
Opportunity - Robust Product Pipeline
Opportunity - Inorganic Growth Drivers
Opportunity - Market Potential: Oncology
Celgene Corporation - Threats
Threat - Highly Competitive Industry
Threat - Stringent Government Regulations
Threat - Uncertainties in R&D
Celgene Corporation - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Celgene Corporation, Recent Deals Summary
Section 5 – Company’s Recent Developments
Celgene Corporation, Recent Developments
Mar 21, 2013: Celgene And bluebird bio To Collaborate With Center For Cell And Gene Therapy To Advance New And Existing CAR T-cell Programs
Mar 04, 2013: Industry Leaders And Academic Researchers Come Together For Innovative Accelerating Cancer Cures Research Symposium
Jan 24, 2013: Celgene Reports Revenue Of $1.45 Billion In Q4 2012
Oct 25, 2012: Celgene Reports Revenue Of $1.4 Billion In Q3 2012
Oct 03, 2012: Leukemia & Lymphoma Society And Celgene Enter Into Partnership To Accelerate Blood Cancer Therapies
Jul 26, 2012: Celgene Reports Revenue Of $1.4 Billion In Q2 2012
Apr 26, 2012: Celgene Reports Revenue Of $1.3 Billion In Q1 2012
Jan 26, 2012: Celgene Reports Revenue Of $1.3 Billion In Q4 2011
Jan 23, 2012: Celgene Elects Richard Barker To Board
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Celgene Corporation, Key Facts
Celgene Corporation, Key Employees
Celgene Corporation, Key Employee Biographies
Celgene Corporation, Major Products and Services
Celgene Corporation, Number of Pipeline Products by Therapy Area
Celgene Corporation, Number of Pipeline Products by Development Stage
Celgene Corporation, Pipeline Products By Therapy Area and Development Phase
Celgene Corporation, History
Celgene Corporation, Other Locations
Celgene Corporation, Subsidiaries
Celgene Corporation, Key Competitors
Celgene Corporation, Ratios based on current share price
Celgene Corporation, Annual Ratios
Celgene Corporation, Interim Ratios
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013
Celgene Corporation, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Celgene Corporation, Pipeline Products by Therapy Area
Celgene Corporation, Pipeline Products by Development Phase
Celgene Corporation, Performance Chart (2008 - 2012)
Celgene Corporation, Ratio Charts
Celgene Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013
Celgene Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013

Eisai Co., Ltd.
Takeda Pharmaceutical Company Limited
Amgen Inc.
Shire Plc
Pharmaceutical Product Development, Inc.
Merck & Co., Inc.
Bristol-Myers Squibb Company
Genta Incorporated

Note: Product cover images may vary from those shown

RELATED PRODUCTS